Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

Rhea-AI Summary

Tevogen (NASDAQ:TVGN) announced significant advancements in its PredicTcell™ AI platform for T cell-based therapies. The beta version has expanded its training dataset to ~1.4 million records and total dataset to over 6.7 billion records, marking a 100-fold increase.

The platform, developed with Microsoft and Databricks, builds upon the alpha version which achieved 92-97% recall levels and 38-43% precision. The beta version analyzes over 10.7 billion data points, including 6.5 billion virology, 4.2 billion genomic, and 416 million oncology datapoints, while expanding training features from 22 to 27.

This advancement could potentially enable T-cell therapies to bind to their targets with unprecedented accuracy, promising increased clinical success rates, shorter development timelines, and improved patient access to life-saving therapies.

Positive

• Massive dataset expansion to 6.7 billion records, a 100-fold increase from alpha version
• High performance metrics with 92-97% recall levels in alpha version
• Partnership with major tech companies Microsoft and Databricks
• Potential to significantly improve clinical success rates and reduce drug development costs

Negative

• Current precision range remains relatively low at 38-43%
• Technology still in beta phase with unproven commercial viability
• Additional capital may be needed to execute business plan
• Faces significant regulatory and development uncertainties

• Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.
• Potential future T cell therapies could reliably bind to their target nearly every time, dramatically raising the probability of success.

WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced significant progress in the development of its proprietary PredicTcell™ platform, designed to accelerate precision immunotherapy development and efficacy through advanced machine learning and transformer-based models. The platform is being developed with the support of Microsoft (Nasdaq: MSFT) and Databricks, leveraging their advanced cloud and data technologies to enable scalability and efficiency.

The alpha version of PredicTcell was trained on more than 124,000 records using transformer-based architecture and 91,000 records using traditional machine learning architecture. The alpha version of the model delivered recall levels of ~92–97% and a precision range of ~38–43%, serving as a proof-of-concept for AI-driven prediction of immunologically active peptide-T cell receptor interactions.

Informed by insights from Tevogen’s proprietary ExacTcell™ platform and positive Phase 1 trial results, PredicTcell Beta aims for significantly higher precision in identifying virology targets. Key advancements include:

• Expanded the training dataset tenfold to approximately 1.4 million records, while the total dataset has grown more than 100-fold to over 6.7 billion records.
• Analyzed more than 10.7 billion data points to construct the training set consisting of 6.5 billion virology datapoints, 4.2 billion genomic datapoints, and 416 million oncology datapoints.
• Expanded the number of features for training the model from 22 to 27.
  

By dramatically scaling its data pipelines and fine-tuning its models, Tevogen.AI could move toward an unprecedented position: T-cell therapies that could accurately bind to their intended target nearly every time. Such predictability would be a transformative breakthrough in medicine, with far-reaching implications:

• Clinical success rates dramatically increased.
• Development timelines shortened, reducing drug costs.
• Greater patient access to life-saving therapies across infectious diseases, oncology, and beyond.
  

“The promise of PredicTcell goes far beyond data,” said Mittul Mehta, CIO and Head of Tevogen.AI. “If our tools continue to deliver as they have so far, Tevogen stands to create T-cell therapies where binding to the target virus or disease isn’t just probable, but nearly guaranteed. That would mean clinical success, faster cures, reduced costs, and ultimately more lives saved.”

“With the right skill and the proper blend of AI and biotechnology, we can scale discoveries in precision medicine once thought impossible. Tevogen’s AI initiative is to raise efficacy standards in T cell–based therapies, cut development costs, and unlock entirely new markets in immunotherapy,” added Ryan Saadi, M.D., M.P.H., Chief Executive Officer of Tevogen Bio.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts
Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

What is Tevogen's PredicTcell™ platform and how does it work?

PredicTcell™ is an AI platform that uses advanced machine learning and transformer-based models to predict immunologically active peptide-T cell receptor interactions, trained on ~1.4 million records and analyzing over 10.7 billion data points.

What are the key performance metrics of Tevogen's PredicTcell™ platform?

The alpha version achieved 92-97% recall levels and 38-43% precision, while the beta version expanded to analyze over 6.7 billion records with 27 training features.

How could PredicTcell™ impact T cell therapy development?

PredicTcell™ could potentially enable T-cell therapies to bind to targets with near-perfect accuracy, leading to higher clinical success rates, shorter development times, and reduced drug costs.

Who are Tevogen's key technology partners for PredicTcell™?

Tevogen is developing PredicTcell™ with support from Microsoft (NASDAQ: MSFT) and Databricks, leveraging their cloud and data technologies for scalability.

What types of data does Tevogen's PredicTcell™ analyze?

PredicTcell™ analyzes 6.5 billion virology datapoints, 4.2 billion genomic datapoints, and 416 million oncology datapoints.